Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Updated August 2022.


Employees say this is a great place to work

Company Overview

About The Company

Alnylam has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA™ (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Novartis.


1,506 U.S.-based Employees


Biotechnology & Pharmaceuticals

Employee Demographics


Company Culture at Alnylam Pharmaceuticals

The employee experience below at Alnylam Pharmaceuticals, compared to a typical company.

Learn More

94% of employees at Alnylam Pharmaceuticals say it is a great place to work compared to 57% of employees at a typical U.S.-based company.

  • Alnylam Pharmaceuticals
  • 94%
  • Typical Company
  • 57%
When I look at what we accomplish, I feel a sense of pride.
People here are willing to give extra to get the job done.
I'm proud to tell others I work here.
I feel good about the ways we contribute to the community.
When you join the company, you are made to feel welcome.

Why Work at Alnylam Pharmaceuticals?

See what employees say about what makes Alnylam Pharmaceuticals a great workplace. These words are drawn from employee comments on the Trust Index™ survey.

Best Workplaces Lists

Great Place To Work® is proud to recognize Alnylam Pharmaceuticals

Don't See Your Company Listed?

Nominate your company today to join Certification Nation